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Abstract
Introduction and Objectives: The traditional approach to target a particular receptor is to design compounds
that bind to the same site as the endogenous ligand, the so-called ‘‘orthosteric site.’’ However, recently the search
has shifted to ligands that can interact with a different region of the receptor protein, the ‘‘allosteric site,’’ since
this approach offers potential pharmacological and therapeutic advantages. The aim of our work was to explore
the benzimidazole heterocycle as a novel scaffold for cannabinoid allosterism.
Materials and Methods: We synthesized a series of novel benzimidazole-2-carboxamides, analogues of
ORG27569, and performed their pharmacological characterization as CB1R allosteric modulators using compe-
titive [3H]-CP55940 and [35S]-GTPcS binding assays.
Results: The benzimidazoles 3 and 4 produced signiﬁcant negative allosteric modulation (NAM) of CP55940
agonism at the mouse CB1R, although are somewhat less potent than the CB1R allosteric cannabinoid ORG27569.
Conclusions: Replacing the indole ring with a benzimidazole ring within the structure of ORG27569 abolished
the binding of the resultant ligands to CB1R, but the modulation on the agonist-induced GTPcS binding was
maintained.
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Introduction
The traditional approach to target a particular receptor
involves designing compounds, agonists or antagonists,
that bind to the same site as the endogenous ligand,
the so-called ‘‘orthosteric site.’’ However, recently, the
search has shifted to ligands that can interact with a
different region of the receptor protein, the ‘‘allosteric
site,’’ since this approach offers potential pharmacolog-
ical and therapeutic advantages.1
One possibility to overcome the limitations of the ‘‘tra-
ditional’’ cannabinoids, interacting with the orthosteric
sites on cannabinoid receptors, is to look for compounds
that can bind to a different (allosteric) site.2,3 However,
only a very limited number of chemical structures
have been investigated as potential allosteric cannabi-
noid ligands (including endogenous and synthetical allo-
steric modulators).4 Among them, worthmentioning are
the indole carboxamides such as ORG27569 (Fig. 1),
ORG27759, and ORG29647,5 and some derivatives of
these compounds,6–9 the urea compound PSNCBAM-
110 and its recently published11 and patented12 analogs,
or the cocaine-related structure RTI-371.13
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Several analogs of ORG compounds have been ex-
tensively studied by Kendall, Lu, and coworkers,7,14,15
but to date, the indole ring has not been replaced,
with the exception of four benzofuran compounds,
which had shown interesting properties.14 Within this
context, we decided to study the possibility of mod-
ifying the nature of the heterocycle in the ORG
compounds, incorporating a benzimidazole ring. To
explore this scaffold, structural and substituent changes
have been undertaken on the benzimidazole, on the pi-
peridine group, and on the length of the amide linker
(Fig. 1). Once synthesized, the afﬁnity of the new com-
pounds for CB1R and CB2R has been measured in com-
petitive [3H]-CP55940 binding experiments, and their
efﬁcacy as allosteric modulators has been evaluated in
[35S]-GTPcS binding assays. Only compounds 3 and
4 showed some activity.
Materials and Methods
Chemistry
The synthesis of compounds 3 and 4 is described
next. Preparation of compounds 5–13 was performed
by a procedure similar to the one of compounds 1–4
(scheme and experimental synthetical details of com-
pounds 5–13, and general synthetical issues are cov-
ered in the Supplementary Data).
5-Chloro-2-(trichloromethyl)-1H-benzimidazole (1)
Methyl trichloroacetimidate (1.90mL, 15.4mmol, 1.1
equivalent [eq]) was added dropwise to a cooled solution
of 4-chloro-o-phenylenediamine (2.00 g; 14.0mmol, 1
eq.) in glacial acetic acid (25mL). At the end of the
addition, the dark reaction mixture was kept at room
temperature for 1 h. Afterward, water (20mL) was
added to facilitate the product precipitation. The
resulting residue was ﬁltered off, washed with water,
and dried under vacuum. It was puriﬁed by medium-
pressure chromatography (Isolera, eluent: hexane/3:7
n-hexane/EtOAc) to give 3.05 g of 1 (80%) as a pale
brown solid, mp: 231–233C. 1H-NMR (300MHz,
DMSO-d6): d 7.73 (bs, H4, 1H); 7.68 (d, Jo= 8.5Hz,
H7, 1H); 7.35 (bd, Jo = 8.5 Hz, H6, 1H); 13C-NMR
(75MHz, DMSO-d6): d 151.8 C2; 139.1 and 136.8
C3a and C7a; 128.2 C5; 124.3 C6; 117.7 and 116.1 C4
and C7; 88.5 CCl3; liquid chromatography/mass
spectrometry (LC/MS) (ES+) tR = 4.7min (94% puri-
ty), m/z = 271 [M +H]+.
5-Chloro-1H-benzimidazole-2-carboxylic acid (2)
1 (1.50 g, 55.6mmol, 1 eq.) was added to a solution of
sodium hydroxide (100mL; 1N) at 0C. The resulting
solution was ﬁltered, and the ﬁltrate was acidiﬁed with
37% hydrochloric acid to pH 4. The precipitate was ﬁl-
tered off, washed twice with both water and ether. The
resulting solid was then dried under vacuum to give
1.06 g (97%) of 2 as a pale brown solid, mp: 159–
161C. 1H-NMR (300MHz, DMSO-d6): d 8.28 (s,
NH, 1H); 7.66 (d, Jm = 2.0Hz, H4); 7.60 (d, Jo = 8.6Hz,
H7); 7.21 (dd, Jo = 8.6Hz, Jm = 2.0Hz, H6); 13C-NMR
FIG. 1. Structure of ORG27569 and of the synthesized benzimidazoles.
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(75MHz, DMSO-d6): d 143.4 COOH and C2; 139.3
and 136.6 C3a and C7a; 126.2 C5; 122.1 C6; 116.4 and
115.2 C4 and C7; MS (ES+), m/z = 197 [M +H]+.
5-Chloro-N-[4-(piperidin-1-yl)phenethyl]-
1H-benzimidazole-2-carboxamide (3)
A mixture of 2 (192mg, 1.0mmol, 1 eq.), PyBOP
(509mg, 1.0mmol, 1 eq.), and NMM (323lL, 3.0mmol,
1 eq.) in DMF (3mL) was stirred at room temperature
for 15min to activate the acid. Then, 2-[4-(piperidin-1-
yl)phenyl]ethanamine hydrochloride (270mg, 1.0mmol,
1 eq.) was added and the mixture was stirred at room
temperature overnight. Afterward, DMF was removed
in vacuo. The residue was dissolved in EtOAc and
washed with water (3 · 30mL). The organic layer was
dried over anhydrous MgSO4, and the solvent was evap-
orated. The residue was puriﬁed by medium-pressure
chromatography (Isolera, eluent: n-hexane /3:7
hexane/EtOAc), obtaining 3 as a white solid (132mg,
36%), mp: 173–176C. 1H-NMR (300MHz, CDCl3):
d 12.78–12.68 (m, Benzimidazole NH, 1H); 8.06
(s, CONH, 1H); 7.75–7.29 (m, H4, H6 and H7, 3H);
7.14 (d, J = 8.2 Hz, Hm, 2H); 6.89 (d, J = 8.2 Hz, Ho,
2H); 3.84–3.74 (m, CONHCH2, 2H); 3.17–3.05 (m,
piperidine NCH2, 4H); 2.93 (t, J = 7.2 Hz, CH2Ar,
2H); 1.78–1.67 (m, piperidine NCH2CH2, 4H); 1.60–
1.52 (m, piperidine NCH2CH2CH2, 2H);
13C-NMR
(75MHz, CDCl3): d 159.5 CONH; 151.0 Cp; 145.9
C2; 143.7 C3a; 141.5 C3a rotamer; 135.2 C7a; 133.2 C7a
rotamer; 130.7 C5; 129.4 Co; 129.0 Cipso; 125.6 C6;
124.4 C6 rotamer; 121.3 C7; 120.2 C7 rotamer; 117.1
Cm; 113.6 C4; 112.7 C4 rotamer; 51.0 piperidine
NCH2; 41.6 CONHCH2; 35.0 CH2Ar; 25.9 piperidine
NCH2CH2; 24.3 piperidine NCH2CH2CH2; LC/MS
(ES+) tR= 2.9min (99% purity), m/z = 383 [M+H]+.
5-Chloro-N-[4-(dimethylamino)phenethyl]-
1H-benzimidazole-2-carboxamide (4)
Amixture of2 (60mg, 1.0mmol, 1 eq.), PyBOP (158mg,
1.0mmol, 1 eq.), and NMM (100lL, 3.0mmol, 1 eq.) in
DMF (3mL) was stirred at room temperature for
15min to activate the acid. Then, 4-(2-aminoethyl)-
N,N-dimethylaniline (50mg, 1.0mmol, 1 eq.) was
added and the mixture was stirred at room temperature
overnight. Afterward, water (30mL) was added to the
reaction mixture. Then, the solid was ﬁltered off,
washed with water, and dried under vacuum, obtaining
4 as a brown solid (61mg, 58%), mp: 187–192C. 1H-
NMR (300MHz, CDCl3): d 12.83 (bs, Benzimidazole
NH, 1H); 8.11 (bs, CONH, 1H); 7.75–7.45 (m, H4 and
H7, 2H); 7.32–7.28 (m, H6, 1H); 7.13 (d, J= 8.2Hz,
Ho, 2H); 6.68 (d, J= 8.2Hz, Hm, 2H); 3.83–3.76 (m,
CONHCH2, 2H); 2.95–2.86 (m, CH2Ar and NMe2,
8H); 13C-NMR (75MHz, CDCl3): d 159.5 CONH;
149.6 Cp; 146.1 C2; 129.5 Co; 126.3 Cipso; 113.3 Cm;
41.7 CONHCH2; 40.9NMe2; 34.8 CH2Ar; LC/MS
(ES+) tR = 3.0 min (92% purity), m/z = 343 [M +H]+.
Pharmacology
Equilibrium binding assay. The equilibrium binding
assays were performed as previously described.16
[35S]-GTPcS binding assay. CP55940 was purchased
from Tocris (Bristol, United Kingdom), [35S]GTPcS
(1250Ci/mmol) from PerkinElmer (Seer Green, Buck-
inghamshire, United Kingdom), GTPcS from Roche
FIG. 2. Synthesis of benzimidazoles 3 and 4.
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Diagnostics (Burgess Hill, West Sussex, United King-
dom), and GDP from Sigma-Aldrich (Poole, Dorset,
United Kingdom).
All [35S]-GTPcS binding assays were carried out with
mouse whole-brain membranes, prepared as described
elsewhere.17 These membranes (5lg of protein per well)
were preincubated for 30min at 30C with adenosine de-
aminase (0.5U/mL). Themembranes were then incubated
with the agonist with a vehicle or modulator for 60min at
30C in assay buffer (50mM Tris-HCl, 50mM Tris-base,
5mMMgCl2, 1mM EDTA, 100mMNaCl, 1mM dithio-
threitol, and 0.1% BSA) in the presence of 0.1 nM [35S]-
GTPcS and 30lM GDP, in a ﬁnal volume of 500lL.
Binding was initiated by the addition of [35S]-GTPcS.
Nonspeciﬁc binding was measured in the presence
of 30lM GTPcS. The reaction was terminated by rapid
vacuum ﬁltration (50mM Tris-HCl, 50mM Tris-base,
and 0.1% BSA) using a 24-well sampling manifold
(Brandel cell harvester) and GF/B ﬁlters that had been
soaked in buffer (50mM Tris-HCl, 50mM Tris-base,
and 0.1% BSA) for at least 24 h. Each reaction tube
was washed six times with a 1.2-mL aliquot of ice-
cold wash buffer. The ﬁlters were oven-dried for at
least 60min and then placed in 3mL of scintillation
ﬂuid (Ultima Gold XR). Radioactivity was quantiﬁed
by liquid scintillation spectrometry.
Results and Discussion
The synthesis of compounds 3 and 4 is depicted in
Figure 2. They were prepared by the coupling reac-
tion of 5-chloro-1H-benzimidazole-2-carboxylic acid
(2) with the corresponding amine in the presence of
the PyBOP reagent and NMM in DMF. Acid 2 was
obtained in good yield by hydrolyzing 5-chloro-2-
(trichloromethyl)-1H-benzimidazole (1) with sodium
hydroxide aqueous solution, followed by acidiﬁcation
with dilute hydrochloric acid.18 In turn, 1 was ﬁrst pre-
pared from 4-chloro-o-phenylenediamine and trichlor-
omethyl acetimidate using a weak acid.
The ability of benzimidazoles 3 and 4 to displace
[3H]-CP55940 from human cannabinoid CB1R or
CB2R transfected into HEK293 EBNA cells was ﬁrst eval-
uated at a compound concentration of 40lM.At this con-
centration, none of the compounds was able to displace
[3H]-CP55940 from CB1R and/or from CB2R (data not
shown). These data suggest that 3 and 4 could be dis-
carded as orthosteric CB1R/CB2R binders, since these
compounds (3 and 4) did not affect the binding afﬁnity
of the cannabinoid receptor agonist CP55940 at 40lM
(Ki CB1R and Ki CB2R ‡40lM). Then, [35S]-GTPcS
FIG. 3. Stimulation of binding of [35S]-GTPcS to
mouse whole-brain membranes by CP55940 in
the presence of vehicle (DMSO, n = 10) or 3 at
10 lM (n = 10) (A), in the presence of vehicle
(DMSO, n= 4) or 3 at 1 lM (n = 4) (B), in the
presence of vehicle (DMSO, n = 4) or 4 at 10 lM
(n = 4) (C), in the presence of vehicle (DMSO,
n= 8) or 4 at 1 lM (n = 8) (D), in the presence of
vehicle (DMSO, n= 4) or ORG27569 at 10 lM
(n = 4) (E), and in the presence of vehicle (DMSO,
n= 4) or ORG27569 at 1 lM (n = 4) (F). Each
symbol represents the mean percentage
stimulation above basal – SEM.
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binding assays in mouse whole-brain membranes were
performed to assess the effect of the synthesized benz-
imidazoles on the functionality of CP55940.
In [35S]-GTPcS binding assays performed with com-
pound 3 or its vehicle (Fig. 3A), CP55940 stimulated
[35S]-GTPcS binding with a mean maximal effect
(Emax) that was signiﬁcantly less in the presence of
3 at 10lM (38.0%) than in its absence (70.2%). The
corresponding mean EC50 values of CP55940 in the
presence and absence of 3 at 10lM were 118.4 and
16.9 nM, respectively, and these EC50 values are not
signiﬁcantly different from each other. In the case of
compound 4 at 10lM (Fig. 3C), CP55940 stimulated
[35S]-GTPcS binding with an Emax that was signiﬁ-
cantly less in the presence of 4 (33.3%) than in its ab-
sence (74.1%). The corresponding mean EC50 values
of CP55940 are not signiﬁcantly different from each
other: 24.5 nM in the presence of compound 4 and
14.1 nM in its absence. However, at 1lM, none of
the compounds 3 and 4 affects the Emax, or indeed
the EC50 of CP55940 (Fig. 3B, D, respectively). These
results indicate that benzimidazoles 3 and 4 produce
signiﬁcant negative allosteric modulation (NAM) of
CP55940 agonism at the mouse CB1R, although they
are somewhat less potent than the CB1R allosteric
cannabinoid ORG27569, which showed efﬁcacy on
CP55940 at 1 lM in this assay (Fig. 3F). The conﬁdence
intervals of these data are covered in the Supplemen-
tary Data (Supplementary Table S1).
According to the results from molecular modeling
studies of the allosteric CB1R binding site of ORG27569
that have been published to date, the main interaction be-
tween this ligand and the receptor, in the presence of
CP55940, occurs between the piperidine nitrogen and
the K3.28(192) amino acid.19 However, there are not
many reported data regarding the importance of the 3-
ethyl substituent or the free NH of the indole. Regarding
the substitution on position 3 of the indole, a recent paper
indicates that a small chain (H orMe) improved CB1R al-
losteric modulation.8 It is noteworthy that in our
hands, replacement of the 3-ethyl group of ORG27569
with a nitrogen (in 3 and 4) affects the efﬁcacy with
which GTPcS binding is allosterically modulated.
Therefore, we performed the alkylation of 3 and 4, lead-
ing to N-substituted compounds in position 3 of the
heterocycle (data not shown). These compounds did
not exhibit any CB1R allosteric modulation in [
35S]-
GTPcS assays (data not shown), thus indicating that
the presence of a free NH in benzimidazoles seems to
be crucial for CB1R allosteric modulation.
Conclusions
In summary, the benzimidazole ring has been explored
as a potential scaffold for developing cannabinoid
allosteric ligands. Thus, a series of benzimidazole-2-
carboxamides has been prepared. Regarding binding
assays, compounds 3 and 4 signiﬁcantly attenuated
the ability of CP55940 to stimulate [35S]-GTPcS binding,
without affecting the orthosteric ligand binding afﬁnity
of [3H]-CP55940 in radioligand competitive assays, sug-
gesting that they may act as CB1R negative allosteric
modulators. In conclusion, replacement of the indole
ring with a benzimidazole ring within the structure of
ORG27569 abolished the binding of the resultant ligands
to CB1R, but the modulation on the agonist-induced
GTPcS binding was maintained.
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CB1R¼ cannabinoid 1 receptor
CB2R¼ cannabinoid 2 receptor
DMF¼ dimethylformamide
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